002166，控制权或生变！停牌！

Core Viewpoint - The actual controller of Rhein Biotech, Qin Benjun, is planning a change in the company's control, leading to a stock suspension and a proposed acquisition of at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. [2][4][9] Group 1: Control Change - Rhein Biotech announced that Qin Benjun is preparing to transfer part of his shares and relinquish some voting rights [4][7] - A "Control Change Intent Agreement" has been signed, but specific transaction details are still under negotiation [7][8] - The change may result in a new controlling shareholder and actual controller for the company [7] Group 2: Acquisition Details - The company plans to acquire at least 80% of Beijing Jinkangpu, which will become a subsidiary and included in the consolidated financial statements [7][14] - The acquisition aims to leverage synergies between Rhein Biotech and Beijing Jinkangpu, enhancing R&D capabilities and market coverage [14] - Beijing Jinkangpu's parent company has extensive experience in the infant food and health supplement sectors, collaborating with well-known dairy companies [11][14] Group 3: Shareholding Structure - As of the end of Q3, Qin Benjun holds 271.39 million shares, representing 36.59% of Rhein Biotech [15][16] - The total market value of Qin's shares is approximately 2.15 billion [16] - The company’s stock price was reported at 8.7 yuan per share, with a total market capitalization of 6.45 billion as of December 9 [18]